USC Donations Drop $100 Million after Puliafito Scandal, Report Says

February 9, 2018: By Joan McKenna

The University of Southern California saw a $100 million drop in contributions in the last half of 2017 in the wake of a scandal involving former ophthalmologist Carmen Puliafito, according to a story published Feb. 7 by The Los Angeles Times.

Donations dropped $45 million, or 55 percent, within USC’s Keck School of Medicine, where Puliafito served as dean from August 2007 to March 2016.

The decline in support followed publication of a Los Angeles Times story in July 2017 alleging that Puliafito used methamphetamine and other drugs and kept company with prostitutes and drug users, sometimes on campus, while he was dean. In the aftermath, the university faced numerous related expenses as it hired crisis managers and launched an investigation into the school’s handling of the scandal.

University officials attributed the decline in contributions to normal fluctuations in fundraising.

Two USC employees involved with fundraising told the LA Times that donors were affected by the scandal and felt the school’s moral compass didn’t fit their own anymore.

USC has transformed its fundraising efforts in recent years. It launched a $6 billion fundraising campaign in 2011 and surpassed its goal in 6 1/2 years, raising as much in that time as it had in the previous 6 1/2 decades combined, the school said.

Puliafito’s own reputation was built around his fundraising prowess, both at USC and Bascom Palmer Eye Institute.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

Allergan Appoints Matthew Walsh as CFO

Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023